Qualification and application of an ELISA for the determination of Tamm Horsfall
     Protein (THP) in human urine and its use for screening of Kidney Stone Disease by Lau, Wai-Hoe et al.
Int. J. Biol. Sci. 2008, 4 
 
215
International Journal of Biological Sciences 
ISSN 1449-2288 www.biolsci.org 2008 4(4):215-222 
© Ivyspring International Publisher. All rights reserved 
Research Paper 
Qualification and application of an ELISA for the determination of Tamm 
Horsfall Protein (THP) in human urine and its use for screening of Kidney 
Stone Disease 
Wai-Hoe Lau1, Wing-Seng Leong2, Zhari Ismail1, and Lay-Harn Gam1 
1.  School of Pharmaceutical Sciences, Universiti Sains Malaysia, USM, Penang, Malaysia. 
2.  Lam Wah Ee Hospital, Penang, Malaysia.  
Correspondence to: Lay-Harn Gam, School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 USM. Penang, Malaysia. 
Telephone: 604-6533888 ext 2208 Fax no: 604-6570017. e-mail: layharn@usm.my 
Received: 2008.04.29; Accepted: 2008.08.02; Published: 2008.08.04 
Kidney stone disease affects 1 - 20% of the general population. At present, the diagnosis of a stone is done using 
radiography method when noticeable symptoms appeared. We developed a non-invasive quantitative assay for 
urinary THP, namely ELISA; whereby our previous study and other reports had shown the usefulness of THP as 
biomarker for kidney stone disease. Since urine is biological fluid that is easily obtainable, this method could be 
used as a screening assay for kidney stone prior to confirmation with radiography. The ELISA gave assay linear-
ity r2 > 0.999 within the range of 109 ng/mL to 945 ng/mL THP. Assay precisions were < 4% (C.V.) for repeat-
ability and < 5% (C.V.) for reproducibility. Assay accuracy range from 97.7% to 101.2% at the various THP con-
centrations tested. Assay specificity and sensitivity were 80% and 86%, respectively. The cut-off points at P < 0.05 
were 37.0 and 41.2 μg/mL for male and female, respectively. The assay is cost effective and rapid whereby the 
cost for assaying each urine sample in duplicate is approximately USD0.35 and within 5 hours, 37 samples can be 
assayed alongside full range of standards and 3 QC samples in each plate. Furthermore, sample preparation is 
relatively easy where urine sample was diluted 10 times in TEA buffer. The usability of the ELISA method for 
diagnosis of kidney stone disease is evaluated with 117 healthy subjects and 58 stone formers. 
Key words: Kidney stone disease, ELISA, Tamm-Horsfall protein, Screening assay 
Introduction 
Kidney stone disease affects 1 - 20% of the general 
population. The lifetime chance of an individual 
forming a kidney stone is 10 - 15% with the peak age of 
onset between 20 and 30 years old [1]. The risk of re-
currence is 74% within 10 years for first-time stone 
formers [2]. Therefore, a rapid and reliable screening 
assay for kidney stones is highly desirable. In 1950, 
Tamm and Horsfall discovered a glycoprotein in urine 
that was named the Tamm Horsfall Glycoprotein 
(THP). THP is the most abundant protein present in 
the urine of healthy subjects [3]. It is secreted by the 
thick ascending limb of the loop of Henle [4, 5]. THP is 
inserted into the luminal cell surface by a glyco-
syl-phosphatidylinositol (GPI)-anchor and then ex-
creted in urine at a rate of 50 - 100 mg/day [6, 7]. It is a 
monomeric glycoprotein of ~ 85 kDa with ~30% car-
bohydrate moiety that is heavily glycosylated by 
polyantennary sialated N-linked glycans [8, 9]. Sialic 
acid plays an important role in maintaining THP func-
tion during kidney stone formation [10]. THP has a 
strong tendency to forming macroaggregates of sev-
eral million Daltons.  
THP excretion decreases in stone formers and 
therefore it was proposed as a potential biomarker for 
kidney stone disease [11, 12]. Hess et al. [13] described 
THP as the major inhibitor to calcium oxalate crystal 
aggregation in the urine of healthy individuals. How-
ever, other reports showed that stone formers excreted 
defective urinary THP that devoid of sialic acid with a 
diminished effect on inhibiting stone formation [10, 
13]. A number of assays have been developed to detect 
THP includes electroimmunodiffusion, gel electro-
phoresis, radioimmunoassay and enzyme-linked im-
munosorbent assays (ELISA). THP quantification has 
been limited by relatively insensitive assays and labo-
rious pretreatment of urine sample i.e. dialysis, gel 
filtration, ultracentrifugation, freezing, incubation 
with detergents and pH adjustment [14]. Most of the Int. J. Biol. Sci. 2008, 4 
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assays require freezing of the urine for 24 hours fol-
lowed by dilution in water or buffer at 1:20 to 1:100 
before analysis in order to keep the THP soluble for 
quantification [11, 12, 14]. 
We developed an ELISA method for quantifying 
urinary THP. Wheat germ from Tirticum vulgaris 
(WGA) that specific to THP [15] was used to coat mi-
crotiter plates for capturing of urinary THP. WGA is a 
type of lectin that is specific to the receptor of THP 
[15]. WGA binds specifically to the di 
N-acetylglucosamine and sialic acid on the receptor of 
THP [15] but bind weakly to human chorionic gonad-
otropin that was excreted abundantly in urine of 
pregnant women [16]. The captured THP was recog-
nized by an anti-THP antibody and the Ab-Ag com-
plexes were then recaptured by a secondary antibody 
tagged with horseradish peroxidase (HRP), the 
amount of THP was quantified based on the intensity 
of the color reaction developed between the HRP and 
its substrate. Its reliability as screening assay for kid-
ney stone disease is determined.  
Methods  
Urine specimen collection 
Urine samples were collected from kidney stone 
patients provided by the Urology Clinic, General 
Hospital, Pulau Pinang and Lam Wah Ee Hospital, 
Pulau Pinang, Malaysia. Two cohorts were recruited in 
this study i.e. 58 stone formers (34 male, 24 female) age 
range from 28 – 74 years and 117 healthy subjects (41 
male, 76 female) age range from 20 – 86 years. The 
stone formers comprise 39 staghorn calculi (23 male, 16 
female) and 19 acute renal calculi (11 male, 8 female). 
All the stone formers were confirmed by radiography 
using Plain Abdominal Radiography (KUB) and/or 
Intravenous Urography (IVU) and they were afflicted 
by partial obstruction and non obstruction kidney 
stones. They have not been treated by surgery or 
medication. Healthy subjects had no previous history 
of kidney stones or other nephrolithiasic related dis-
eases included staffs and students of the School of 
Pharmaceutical Sciences, USM and nurses from the 
nursing institute of Lam Wah Ee Hospital, Penang. The 
exclusion criterion for urine is a urinary creatinine 
concentration < 2.00 mmol/L or >19.00 mmol/L, 
normal range is 2.20 – 19.00 mmol/L based on the 
Cayman Chemical Creatinine Assay. Aliquots urine 
samples were stored at -20oC prior to the assay. 
Urinary Creatinine Assay  
Creatinine assay was carried out according to 
Cayman Chemical Creatinine Assay (Cayman Chemi-
cal Company, UK). The assay relies on Jaffe’s reaction, 
wherein a yellow or orange color is formed when the 
metabolites are treated with alkaline picrate [17]. The 
color derived from the creatinine is destroyed at acidic 
pH. The difference in color intensity measured at 
OD495 before and after acidification is proportional to 
the creatinine concentration [17]. A creatinine standard 
curve was constructed for urine creatinine concentra-
tion determination.  
Materials for ELISA  
Capture material used for coating was WGA, a 
type of lectin from Triticum vulgaris (Sigma) and was 
purified by affinity chromatography. The primary an-
tibody was a polyclonal anti-THP antibody (Biomedi-
cal Technologies Inc, USA) raised in rabbit and was 
claimed to have no significant cross reaction with other 
proteins by manufacturer. The secondary antibody 
was goat anti-rabbit IgG (H+L) horseradish peroxidase 
conjugate (BioRad). Substrate was TMB (3,3’,5,5’ 
Tetramethylbenzine, 1 mg) (Sigma). TMB substrate 
solution was freshly prepared by dissolving a tablet of 
TMB in 1 mL of dimethyl sulfoxide (DMSO) (Sigma) 
and added to 9 mL of 0.05 M phosphate-citrate buffer, 
pH 5.0. A volume of 2 μL 30% H2O2 was added to 10 
mL of substrate solution.  
Preparation of Standards and QC Materials 
The standard THP was prepared from pooled 
normal urines using salt precipitation (1mL urine : 
0.27g ammonium sulphate) and calibrated against 
commercial THP (Biomedical Technology, Inc., 1 
μg/μL). The standard had a concentration of 945 
ng/mL THP and was serial diluted to produce solu-
tions with THP concentrations of 417, 236, 165, 123 and 
109 ng/mL. The standards were used to construct 
standard curves for the assay. For long term storage, 
the standards were lyophilized, stored at -20oC and 
re-suspended in TEA buffer (0.5% Triton X-100, 20 mM 
EDTA, pH 7.5) before use. The lyophilized standards 
were stable for at least 6 months. In addition, three 
quality control (QC) samples at THP concentrations 
908, 538 and 123 ng/mL were prepared in TEA buffer 
and labeled QC1, QC2 and QC3, respectively. The QC 
samples were aliquoted in microcentrifuge tubes at 300 
μL/tube. For long term storage, the QC samples were 
lyophilized, stored at -20oC and re-suspended in TEA 
buffer before use. 
Coating of Microtiter Plate 
Each well on the 96-wells microtiter plate (Max-
isorp™, Nunc) was coated with 100 μL of 10 μg/mL 
lectin WGA in coating buffer [5.0 mM Na2CO3, 34.9 
mM NaHCO3, 0.02% (v/v) NaN3, pH 9.6]. The plates 
were covered with parafilm and incubated at 4oC 
overnight with shaking (100 rpm) on an orbital shaker 
(Protech). The plates were washed five times with Int. J. Biol. Sci. 2008, 4 
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freshly prepared washing buffer (0.1% Tween 20 in 10 
mM phosphate buffer saline (PBS) pH 7.2 for 5 min 
each. The unoccupied sites on the microtiter plates 
were blocked with 200 μL blocking buffer (3% BSA in 
10 mM PBS, pH 7.2) and incubated at room tempera-
ture for 2 hours with a slow rotation (50 rpm) on the 
orbital shaker. The plate was washed five times with 
washing buffer for 5 min each wash and dried in an 
oven at 37oC for 3 hours or until thoroughly dried. 
Finally, the plates were cooled to room temperature 
and sealed with an adhesive plate seal, wrapped in 
aluminum foil and stored at 4oC. 
ELISA Screening Procedure for THP Measurement 
WGA coated plates were brought to room tem-
perature before use. The standards and QC samples 
were vortexed gently and added at 100 μL/well into 
the coated microtiter plate wells. The frozen samples 
were stabilized at room temperature and diluted 1:10 
in TEA buffer. Urine samples and standards (109 – 945 
ng/mL) were run in duplicate, and QC samples (908 
ng/mL, 538 ng/mL and 123 ng/mL) were run in trip-
licate. TEA buffer was used as blank. After 1 hour in-
cubation at 37oC, the plates were washed five times 
(rotation, 50 rpm) with 300 μL freshly prepared wash 
b uffe r ( 0. 1%  T w een  2 0 in  1 0 m M PBS , p H 7. 2).  T h e 
plates were placed top down on absorbent paper to 
remove residual buffer. Hundred microliter of 1:10,000 
dilution anti-THP antibody in antibody diluent buffer 
(2% BSA, 0.1% Tween 20, 0.02% NaN3 in 10 mM PBS, 
pH 7.2) was dispensed in each well and the plates were 
incubated at 37oC for 1 hour. The plates were washed 
five times (rotation, 50 rpm) with 300 μL of freshly 
prepared wash buffer and the residual buffer was re-
moved on absorbent paper. The plates were incubated 
at 37oC for 1 hour after adding the same volume of 
goat anti-rabbit IgG (H+L) horseradish peroxidase 
conjugate diluted 1:3,000 in antibody diluent. The 
plates were washed five times (rotation, 50 rpm) with 
300 μL of freshly prepared wash buffer and residual 
buffer was removed on absorbent paper.  
Colour was developed by adding 100 μL of TMB 
substrate solution to each well. The plates were incu-
bated on orbital shaker (100 rpm) for 15 min at room 
temperature in the dark. The reaction was stopped by 
adding 100 μL of 4 M H2SO4 to each well. OD450 and 
OD620 (Thermo Labsystems Multikan Ascent, Finland) 
were read immediately. Urinary THP concentration 
was determined by referring to the standard curve.  
SDS-PAGE for THP Measurement  
The aliquot urine (1 mL) was thawed to room 
temperature and then added with 0.27 g ammonium 
sulphate, (NH4)2SO4. After vortex-mixing for 2 minute, 
the urine was centrifuged at 10,000 rpm for 20 minutes 
at 20oC and the supernatant decanted. The pellet was 
collected and dissolved in 80 μL of solubilizing buffer 
[10 mM Tris, 1 mM EDTA, 1% (w/v) SDS, pH 8.8] and 
vortex-mixed gently for 2 minutes. The mixture was 
then added with 20 μL reducing sample buffer, vor-
tex-mixed and heat at 100oC for 10 minutes. After the 
mixture cool to room temperature, 10 μL of the mix-
ture was loaded into each well of mini-slab gel. One 
microliter of the commercial THP standard (1 μg/μL) 
was loaded in separated well alongside the samples. 
Electrophoresis system used for quantification of THP 
was mini-slab gel (Protean 3, BioRad) composed of 4% 
stacking gel and 10% resolving gel with a gel thickness 
of 0.75 mm and gel size 8 x 7 cm. The electrophoresis 
run was at 200 volt for 50 minutes. The relative inten-
sity of the bands was analyzed using Quantity One 1-D 
software of VersaDoc Imaging System (BioRad).  
Assay Validation 
Urine samples from 117 healthy subjects and 58 
stone formers were assayed using a reference method 
namely SDS-PAGE, where the intensity of THP bands 
was quantify relatively to commercial THP at 1 μg/μL 
concentration. Using SDS-PAGE as the reference 
method, we defined true positive (TP) as urine with 
THP concentration below the cut-off value set when 
measured with both ELISA and SDS-PAGE methods 
while true negative (TN) as urine with THP concen-
tration above the cut-off value set when measured 
with both ELISA and SDS-PAGE methods. In contrary, 
false positive (FP) were urine with THP concentration 
above cut-off value with SDS-PAGE but below cut-off 
value with ELISA and vice-versa with false negative 
(FN) urine. Sensitivity is calculated as TP/ (TP + FN) 
whereas specificity is TN/ (TN + FP) [18]; the results of 
both calculations are expressed as percentages. 
Precision of the assay included repeatability and 
reproducibility [18]. The repeatability (within day 
precision) was calculated by the coefficient of variation 
(C.V.) for each set of the QC materials that were run on 
the same day, whereas reproducibility (between day 
precision) was calculated from the average of the 
within assay precision of each QC materials analyzed 
in three runs at different day. Assay accuracy was 
percentage of the average concentration of standard 
THP as compared to the reported concentration of the 
commercial THP.  
Data analysis 
Data was analysed by using the Statistical Pack-
age for Social Sciences (SPSS, version 15.0). For the 
correlation studies, Pearson correlation coefficient was 
employed and the level of significance was set to alpha 
= 0.01. Student’s t-test was used to determine statistical 
significance between cohort groups (alpha = 0.05). Int. J. Biol. Sci. 2008, 4 
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Chi-square test was applied for correlation analysis 
between ELISA method and the reference method, 
SDS-PAGE. 
Results 
WGA coated mircotiter plates were prepared in 
batch-wise and stored at 4˚C. The plates were brought 
to room temperature before use. The optimum plate 
coating concentration for WGA was tested by coating 
the plate with a series of WGA concentration range 
from 1 – 100 μg/mL. The coated plates were then 
tested with non-diluted and a range of diluted urine 
from 1:5 to 1:100 dilution (Figure 1). At 1:10 urine di-
lution, the optimum WGA concentration for plate 
coating was found to be 10 μg/mL, where binding of 
urinary THP to WGA was a linear function from 1 – 10 
μg/mL WGA, increasing in WGA concentration after 
10 μg/mL does not improve the OD of the assay. Bo-
vine serum albumin (BSA) was used to block the 
non-lectin binding sites on the plate since THP does 
not bind to BSA [19]. The WGA microtiter plates were 
sealed and stored at 4oC where they were stable for at 
least 6 weeks. Aggregation of THP results in reduced 
detection of the glycoprotein, optimum urine dilution 
with maximum disaggregation of THP occurring at 
1:10 dilution (Figure 1). Increasing the urine dilution 
beyond this point reduced the detection of THP. The 
optimal primary and secondary antibody dilutions 
were found at 1:10,000 and 1:3,000, respectively (Fig-
ure 2). 
We validated the ELISA based on assay linearity, 
accuracy, repeatability and reproducibility. The assay 
had a linearity of r2 > 0.999 for the THP concentration 
range from 109 ng/mL to 945 ng/mL. The assay ac-
curacy range from 97.7% to 101.2% over the range of 
THP concentrations from 109 ng/mL to 945 ng/mL 
(Table 1). The precision (C.V.) of each QC samples in 
triplicates was consistently < 10% (Table 2). Assay re-
peatability was < 4% C.V. and assay reproducibility 
was < 5% C.V. as measured by using the three QC 
samples (Table 2).   
 
Table 1: Accuracy of the assay 
Commercial  
THP concentration (ng/mL) 
standard THP concentration  
(ng/mL) 
(n=3) 
 1  2  3 
Mean standard   
THP concentration 
(ng/mL) 
Standard Deviation (SD)  Coefficient of  
Variation (C.V.) 
Accuracy
945.67 942.38  943.47  943.32  943.06  0.59  0.06  99.7% 
417.50 428.14  427.55  423.10  426.26  2.76  0.65  102.1% 
236.33 232.68  229.83  239.00  233.84  4.69  2.01  99.0% 
165.50 163.98  156.43  164.45  161.62  4.50  2.79  97.7% 
123.33 125.16  128.67  120.76  124.86  3.97  3.18  101.2% 
109.33 105.33  111.70  107.04  108.02  3.30  3.05  98.8% 
 
Table 2: The repeatability and precision of the assay. The measurements of QC materials were carried out over 3 days. 
Repeatability (within day precision) 
THP concentration (μg/mL)  OD reading 
QC 1  QC 2  QC 3 
1 905.33  561.20  126.83 
2 851.13  540.94  121.57 
3 921.14  513.05  122.10 
4 855.34  556.39  123.00 
5 816.35  538.13  129.57 
6 816.02  513.45  127.14 
Average 860.89  537.19  125.04 
Standard Deviation  44.11  20.53  3.26 
Coefficient of Variation  5.1%  3.8%  2.6% 
Reproducibility (between day precision) 
THP concentration (μg/mL)  OD reading (n=3) 
QC 1  QC 2  QC 3 
Day 1  829.23  535.99  132.74 
Day 2  908.31  538.40  123.50 
Day 3  896.10  593.43  126.57 
Average 877.88  555.94  127.60 
Standard Deviation  42.57  32.49  4.71 
Coefficient of Variation  4.9%  5.8%  3.7% 
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Figure 1: Determination of the optimal concentration of WGA 
for coating onto microtiter plate. A series of diluted WGA from 
1 - 100 μg/mL were investigated at a serial diluted urine (1:5, 
1:10, 1:20, 1:40, 1:80, 1:100) and non-diluted urine. The 
anti-THP dilution and secondary HRP conjugate dilution were 
1:10,000 and 1:3,000, respectively. The optimum WGA coating 
concentration was 10 μg/mL for urine diluted at 1:10. 
 
Figure 2: Determination of the optimal anti-THP dilution and 
secondary antibody dilution for THP measurement. A serial 
dilution of anti-THP from 1:2,500 – 1:280,000 in antibody 
diluent were evaluated in three different dilution factor of sec-
ondary antibody that were 1:1,000, 1:3,000 and 1:8,000 diluted 
in same buffer, respectively. The microtiter plate was coated 
with 10 μg/mL WGA. 
SDS-PAGE was used to separate the urinary 
proteins and THP band was detected at 97 kDa (Figure 
3). The relative intensity of urinary THP to standard 
THP was used to estimate the concentration of urinary 
THP. Figure 4 shows the scatter plot of THP as meas-
ure by ELISA and SDS-PAGE where the THP concen-
tration by ELISA was correlated positively to that of 
SDS-PAGE (r = 0.648, P = 0.0004). 
 
Figure 3: Electrophoretic mobility of commercial THP and 
standard THP used for THP quantification in reference 
SDS-PAGE method. THP was detected at 97 kDa. Lane 1: 
molecular markers, lane 2 – 4: commercial THP and lane 5 – 8: 
urinary THP from healthy subjects after salt precipitation. 
 
Figure 4: The correlation between ELISA and SDS-PAGE 
methods in measurement of urinary THP concentrations. The □ 
symbols represent an individual urine sample with its corre-
sponding THP concentrations as measured by the methods. The 
THP concentrations assayed by ELISA method was correlated 
positively to SDS-PAGE (r = 0.648, P = 0.0004). The level of 
significance according to Pearson correlation of coefficient was 
set to alpha = 0.01. 
Figure 5 shows a strong positive correlation (r = 
0.649,  P = 0.0002) between THP concentrations and 
THP excretions (THP/Creatinine ratio) as measured 
by ELISA. By using description statistic analysis, the 
95% confident interval of THP concentration in the 
healthy subjects was 55.00 – 77.90 μg/mL for male and 
70.70 – 96.10 μg/mL for female. The THP excretion for 
female healthy subjects was significantly higher (THP 
excretion = 12.32 ± 0.86 mg/mmol, P = 0.029) than that Int. J. Biol. Sci. 2008, 4 
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of their counterpart (Table 3). There was no significant 
difference in THP concentration or THP excretion due 
to sex for stone formers. However significant differ-
ences in the THP concentration (26.00 ± 2.2 μg/mL, P = 
0.0002) and THP excretion (4.02 ± 0.40 mg/mmol, P = 
0.0001) were observed between stone formers and 
healthy subjects (Table 3).  
 
Figure 5: The correlation between THP concentration and THP 
excretion measured by ELISA. The □ symbols represent an 
individual urine sample with its corresponding THP concentra-
tion and THP excretion. The THP concentration was correlated 
positively to THP excretion (r = 0.649, P = 0.0002). The level of 
significance according to Pearson correlation of coefficient was 
set to alpha = 0.01. 
Table 3: The average age, Creatinine concentration, THP con-
centration and THP/Creat ratio in healthy subjects, stone form-
ers and subgroup of stone formers 
 No.  of 
sample 
Age 
(Age 
range) 
(Years) 
Creatinine 
concentra-
tion 
(mmol/L) 
THP con-
centration 
(μg/mL) 
THP/Creat 
ratio 
(mg/mmol)
Healthy 
subjects 
117  32 (18 – 
86) 
8.14 ± 0.40  77.66 ± 4.68  11.23 ± 0.68
Male  41  52 (19 – 
86) 
9.15 ± 0.74  67.05 ± 5.97  9.25 ± 1.02 
Female  76  21 (18 – 
60) 
7.59 ± 0.46  83.38 ± 6.37  12.30 ± 
0.86ª 
Stone 
formers 
58  52 (28 – 
74) 
7.94 ± 0.54  26.03 ± 2.21*  4.02 ± 0.40† 
Male  34  52 (36 – 
74) 
7.50 ± 0.67  24.56 ± 2.56  4.06 ± 0.55 
Female  24  52 (28 – 
68) 
8.57 ± 0.88  28.10 ± 3.96  3.95 ± 0.58 
Subgroup 
of stone 
formers 
       
Staghorn 
calculi 
39  50 (29 – 
67) 
8.62 ± 0.71  26.80 ± 3.02  3.86 ± 0.53 
Acute 
renal 
calculi 
19  55 (28 – 
74) 
6.55 ± 0.63  24.45 ± 2.76  4.34 ± 0.58 
Footnote: All the value expressed as mean ± SE. Symbol  ªindicates 
significant compared with male healthy subjects, P = 0.029; * sig-
nificant compared with healthy subjects, P = 0.0002 and † significant 
compared with healthy subjects, P = 0.0001. 
 
Figure 6 shows the distribution of THP concen-
tration detected in healthy subjects and the stone 
formers. The best fit line to distinguish healthy subjects 
from stone formers was found at 37.00 μg/mL and 
41.20 μg/mL THP concentrations (P < 0.05) for male 
and female, respectively. Using these cut off values, 
the specificity and sensitivity of the assay were 80% 
and 86%, respectively (Table 4).   
 
 
Figure 6: Establishing of cut-off points for ELISA. The o 
symbols represent individual urinary THP concentration. The 
horizontal line indicated cut-off values selected for ELISA. The 
selected cut-off value for male was 37.00 μg/mL and for female 
was 41.20 μg/mL. The number of healthy subjects and stone 
formers tested were 117 and 58, respectively. 
Table 4: Sensitivity and specificity of the developed ELISA. 
SDS-PAGE method   
Quantitatively 
high of urinary 
THP 
Quantitatively 
low of urinary 
THP  
Quantitatively 
high of urinary 
THP 
94 8  ELISA 
method 
Quantitatively 
low of urinary 
THP 
23 50 
 
ELISA performance 
 
 
Specificity = 80% 
 
 
Sensitivity = 86%
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Discussion 
Tamm Horsfall glycoprotein has been identified 
as a useful urinary biomarker to determine the forma-
tion of a kidney stone. Upon evaluation of 117 healthy 
subjects and 58 stone formers by the currently devel-
oped ELISA, we found that THP can be used as a re-
liable biomarker for screening of kidney stone disease. 
The used of THP as biomarker for kidney stone disease 
was verified using SDS-PAGE, whereby a positive 
correlation (r = 0.648, P = 0.0004) between the 
SDS-PAGE and ELISA was observed. Although it is 
based on the common ELISA principle, we have 
shown that it is a cost effective and reliable screening 
assay.  
In the preparation of the microtiter plate for cap-
turing the urinary THP, WGA that is specific to THP is 
chosen. Binding of WGA to THP is through the di 
N-acetylglucosamine and sialic acid on the receptor of 
THP [15], however reports had shown stone formers 
excreted molecular defective urinary THP that devoid 
of sialic acid [10, 13] and thus may lower the detection 
of THP in the stone formers by ELISA. However, since 
low THP detection indicates stone formation, it will 
not interfere with the interpretation of positive result 
for stone formation. Nevertheless, we believe that low 
THP in the stone formers are of pathogenic importance 
and is due to a qualitative factor that is depressed 
synthesis or decreased cellular secretion of THP [11, 
20] rather than quantitative defect. The binding of THP 
to the WGA is proportional to the amount of free THP 
in the urine as aggregation of THP results in hidden 
binding sites. The optimum urine dilution with 
maximum amount of free THP was found to be at 1:10 
urine dilution. In addition, TEA buffer was found to be 
the best dilution buffer for the samples, standards and 
QCs. Whereby it contains Triton X-100 that enhances 
THP dissociation and EDTA that reduces the effects of 
Ca2+ chelation [14]. The pH of TEA buffer at 7.5 helps 
to solubilize THP and keeping it in a homogenous 
form [14, 21, 22]. Freezing of urine sample for 24 hours 
prior to analysis is required to produce consistent and 
reproducible results, which is agreed with those of 
Kobayashi & Fukuoka [21] and Goodall & Marshall 
[23]. Antibody is the most costly item in the develop-
ment of immunoassay based technique. Therefore, it 
d e t e r m i n e s  t h e  c o s t  o f  t h e  a s s a y .  I n  t h i s  s t u d y ,  w e  
minimized the wastage of antibody by selecting an 
optimum antibody dilution with the least amount of 
antibody usage but sufficient to give good sensitivity 
of the assay. The developed assay was validated to 
ensure its reliability in providing useful, consistent 
results [18].  
Previous publications have shown that calcium 
stone formers as a group do not have reduced levels of 
urinary THP that may cause by renal obstruction and 
reduced renal function [24], although uric acid stone 
formers might [25]. In this study, urine was collected 
from patients irrespective of stone types whom were 
afflicted with partial or non obstructing stones, the 
data shown that reducing of urinary THP does not 
correspond to the degree of renal obstruction. 
Urinary creatinine concentration is used as the 
correction factor for the effect of urine hydration on 
analyte concentration [26]. We used urinary creatinine 
concentration to estimate daily THP excretion, which 
was expressed as THP/Creat ratio. False positive sam-
ples were the main reason for reduced specificity of the 
assay. 20% of the healthy subjects had low THP con-
centration by ELISA but was found otherwise with 
SDS-PAGE. These healthy subjects were with no pre-
vious records of kidney stone disease and no symp-
toms of kidney stone disease at the time when urine 
was collected. False positive results detected in healthy 
subjects may be attributed by self-aggregation of THP 
molecules in acidic urine [12, 27], variation in sialic 
acid content of THP [10] and reduce in THP excretion 
in acidic urine [28]. In contrary, 14% of the stone 
formers was found to have high THP concentration by 
ELISA but low with SDS-PAGE, Since acidic urine may 
cause aggregation of THP, we adjusted the pH of these 
samples to 7.4 prior to SDS-PAGE analysis and detect 
no significant change in THP intensity.  
Despite of these exceptional cases, the rest of the 
healthy subjects and stone formers can be diagnosed 
correctly using the currently developed assay. The 
assay can be effectively used as a method for predic-
tion of kidney stone disease, whereby the patients 
whom were presented with certain clinical symptoms 
can be screened using this assay.  
The cost of assaying each sample in duplicate is 
approximately USD0.35 and within 5 hours, 37 sam-
ples can be assayed alongside full range standards to 
construct a calibration curve and 3 QCs in each plate, 
whereby an analyst will be able to handle 3 plates con-
currently. Furthermore, sample preparation is rela-
tively easy where urine sample was diluted 10 times in 
TEA buffer. In view that kidney stone disease is the 
most common nephrolithiasic related disease, this 
n o n - i n v a s i v e  E L I S A  m e t h o d  m a y  b e  t h e  a n s w e r  f o r  
screening of kidney stone disease prior to confirmation 
by using radiogram. 
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